Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Methylphenidate and risk of serious cardiovascular events in adults.

Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, Cziraky MJ, Strom BL, Hennessy S.

Am J Psychiatry. 2012 Feb;169(2):178-85. doi: 10.1176/appi.ajp.2011.11010125.

PMID:
22318795
2.

ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV.

JAMA. 2011 Dec 28;306(24):2673-83. doi: 10.1001/jama.2011.1830. Epub 2011 Dec 12.

3.

Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults.

Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, Cziraky MJ, Strom BL, Hennessy S.

PLoS One. 2013;8(1):e52991. doi: 10.1371/journal.pone.0052991. Epub 2013 Jan 30.

4.

Cardiovascular events and death in children exposed and unexposed to ADHD agents.

Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S.

Pediatrics. 2011 Jun;127(6):1102-10. doi: 10.1542/peds.2010-3371. Epub 2011 May 16.

5.

[Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].

Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC.

Arch Pediatr. 2014 Jan;21(1):108-12. doi: 10.1016/j.arcped.2013.11.001. Epub 2013 Dec 3. French.

PMID:
24309201
6.

Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.

Roumie CL, Choma NN, Kaltenbach L, Mitchel EF Jr, Arbogast PG, Griffin MR.

Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1053-63. doi: 10.1002/pds.1820.

PMID:
19637402
7.

Lower risk of major cardiovascular events associated with adherence to colesevelam HCI.

Ye X, Qian C, Liu J, St Peter WL.

Pharmacotherapy. 2013 Oct;33(10):1062-70. doi: 10.1002/phar.1317. Epub 2013 Jun 24.

8.

Atypical antipsychotic drugs and the risk of sudden cardiac death.

Ray WA, Chung CP, Murray KT, Hall K, Stein CM.

N Engl J Med. 2009 Jan 15;360(3):225-35. doi: 10.1056/NEJMoa0806994. Erratum in: N Engl J Med. 2009 Oct 29;361(18):1814.

9.

Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.

Westover AN, Halm EA.

BMC Cardiovasc Disord. 2012 Jun 9;12:41. doi: 10.1186/1471-2261-12-41. Review.

10.

ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk.

Kratochvil CJ.

Am J Psychiatry. 2012 Feb;169(2):112-4. doi: 10.1176/appi.ajp.2011.11111703. No abstract available.

PMID:
22318789
11.

Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study.

Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, Zito J, Shuster JJ, Olfson M.

BMJ. 2012 Jul 18;345:e4627. doi: 10.1136/bmj.e4627.

12.

Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.

Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR.

Ann Intern Med. 2012 Nov 6;157(9):601-10. doi: 10.7326/0003-4819-157-9-201211060-00003.

13.

Occupational class and incidence rates of cardiovascular events in middle aged men in Japan.

Li Q, Morikawa Y, Sakurai M, Nakamura K, Miura K, Ishizaki M, Kido T, Naruse Y, Suwazono Y, Nakagawa H.

Ind Health. 2010;48(3):324-30.

14.

NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease.

Kohli P, Steg PG, Cannon CP, Smith SC Jr, Eagle KA, Ohman EM, Alberts MJ, Hoffman E, Guo J, Simon T, Sorbets E, Goto S, Bhatt DL; REACH Registry Investigators.

Am J Med. 2014 Jan;127(1):53-60.e1. doi: 10.1016/j.amjmed.2013.08.017. Epub 2013 Nov 23.

PMID:
24280110
15.

Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.

Hennessy S, Schelleman H, Daniel GW, Bilker WB, Kimmel SE, Guevara J, Cziraky MJ, Strom BL.

Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):934-41. doi: 10.1002/pds.1992.

PMID:
20623519
16.

Atrial fibrillation is an independent risk factor for ventricular fibrillation: a large-scale population-based case-control study.

Bardai A, Blom MT, van Hoeijen DA, van Deutekom HW, Brouwer HJ, Tan HL.

Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1033-9. doi: 10.1161/CIRCEP.114.002094. Epub 2014 Sep 18.

17.

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

Winterstein AG, Gerhard T, Shuster J, Saidi A.

Pediatrics. 2009 Jul;124(1):e75-80. doi: 10.1542/peds.2008-3138.

18.

ADHD drugs and serious cardiovascular events in children and young adults.

Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA.

N Engl J Med. 2011 Nov 17;365(20):1896-904. doi: 10.1056/NEJMoa1110212. Epub 2011 Nov 1.

19.

Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study.

Gudbjornsson B, Thorsteinsson SB, Sigvaldason H, Einarsdottir R, Johannsson M, Zoega H, Halldorsson M, Thorgeirsson G.

Eur J Clin Pharmacol. 2010 Jun;66(6):619-25. doi: 10.1007/s00228-010-0789-2. Epub 2010 Feb 16.

PMID:
20157701
20.

Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.

Kalousová M, Zima T, Krane V, März W, Wanner C, Tesař V, Drechsler C; German Diabetes and Dialysis Study Investigators.

Atherosclerosis. 2014 Oct;236(2):263-9. doi: 10.1016/j.atherosclerosis.2014.07.003. Epub 2014 Jul 12.

Supplemental Content

Support Center